Outlook Therapeutics (NASDAQ:OTLK) Receives “Buy” Rating from HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $30.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. BTIG Research decreased their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.07.

Outlook Therapeutics Stock Performance

Shares of NASDAQ:OTLK opened at $2.23 on Friday. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The company has a 50-day simple moving average of $2.70 and a 200-day simple moving average of $5.34. The stock has a market capitalization of $55.55 million, a price-to-earnings ratio of -0.25 and a beta of 0.53.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.06. As a group, research analysts forecast that Outlook Therapeutics will post -2.33 EPS for the current fiscal year.

Institutional Trading of Outlook Therapeutics

A number of institutional investors have recently added to or reduced their stakes in OTLK. AQR Capital Management LLC purchased a new position in Outlook Therapeutics in the second quarter valued at about $75,000. Christensen King & Associates Investment Services Inc. acquired a new stake in shares of Outlook Therapeutics in the 3rd quarter worth approximately $55,000. Barclays PLC increased its stake in Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Outlook Therapeutics by 55.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after purchasing an additional 18,287 shares during the last quarter. Finally, State Street Corp boosted its position in Outlook Therapeutics by 10.0% during the third quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after purchasing an additional 21,201 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.